User profiles for J. M. Canals

Joan-Miquel Canals

Rovira i Virgili University
Verified email at urv.cat
Cited by 3397

Disease‐specific phenotypes in dopamine neurons from human iPS‐based models of genetic and sporadic Parkinson's disease

…, M Ezquerra, B Patel, A Giralt, JM Canals… - EMBO molecular …, 2012 - embopress.org
Induced pluripotent stem cells (iPSC) offer an unprecedented opportunity to model human
disease in relevant cell types, but it is unclear whether they could successfully model age‐…

Neuroprotection by neurotrophins and GDNF family members in the excitotoxic model of Huntington's disease

J Alberch, E Perez-Navarro, JM Canals - Brain research bulletin, 2002 - Elsevier
Huntington’s disease is a neurodegenerative disorder characterized by a selective degeneration
of striatal projection neurons, which deal with choreic movements. Neuroprotective …

Induction of a midbrain dopaminergic phenotype in Nurr1-overexpressing neural stem cells by type 1 astrocytes

…, P Åkerud, DS Castro, PC Holm, JM Canals… - Nature …, 1999 - nature.com
The implementation of neural stem cell lines as a source material for brain tissue transplants
is currently limited by the ability to induce specific neurochemical phenotypes in these cells. …

Neurotrophic factors in Huntington's disease

J Alberch, E Pérez-Navarro, JM Canals - Progress in brain research, 2004 - Elsevier
Huntington's disease is a neurodegenerative disorder characterized by the selective loss of
striatal neurons and, to a lesser extent, cortical neurons. The neurodegenerative process is …

Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's …

JM Canals, JR Pineda, JF Torres-Peraza… - Journal of …, 2004 - Soc Neuroscience
The mechanism that controls the selective vulnerability of striatal neurons in Huntington's
disease is unclear. Brain-derived neurotrophic factor (BDNF) protects striatal neurons and is …

Neuroprotection through delivery of glial cell line-derived neurotrophic factor by neural stem cells in a mouse model of Parkinson's disease

P Åkerud, JM Canals, EY Snyder… - Journal of …, 2001 - Soc Neuroscience
Neural stem cells (NSCs) have been proposed as tools for treating neurodegeneration
because of their capacity to give rise to cell types appropriate to the structure in which they are …

Influence of ethanol concentration on the extraction of color and phenolic compounds from the skin and seeds of Tempranillo grapes at different stages of ripening

R Canals, MC Llaudy, J Valls, JM Canals… - Journal of Agricultural …, 2005 - ACS Publications
The aim of this paper is to study how grape ripeness and ethanol concentration affect the
extraction of color and phenolic compounds from skins and seeds during the maceration/…

Altered P2X7‐receptor level and function in mouse models of Huntington's disease and therapeutic efficacy of antagonist administration

…, R Gómez-Villafuertes, JM Canals… - The FASEB …, 2009 - Wiley Online Library
The precise mechanism by which mutant huntingtin elicits its toxicity remains unknown.
However synaptic alterations and increased susceptibility to neuronal death are known …

[HTML][HTML] Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase

M Borrell-Pagès, JM Canals… - The Journal of …, 2006 - Am Soc Clin Investig
There is no treatment for the neurodegenerative disorder Huntington disease (HD). Cystamine
is a candidate drug; however, the mechanisms by which it operates remain unclear. We …

Translating cell therapies for neurodegenerative diseases: Huntington's disease as a model disorder

…, LJ Mills, C Drew, SA Goldman, JM Canals… - Brain, 2022 - academic.oup.com
There has been substantial progress in the development of regenerative medicine strategies
for CNS disorders over the last decade, with progression to early clinical studies for some …